Description

German biotechnology company CytoTools AG, established in 2000, specializes in developing innovative, disease-modifying therapies. The company leverages its unique portfolio of proprietary small-molecule compounds and biological agents to address unmet medical needs across various therapeutic domains, including dermatology, cardiovascular health, urology, and oncology. At the forefront of its clinical efforts is DermaPro, which has successfully completed Phase III trials for diabetic foot ulcers (DFU) in India. This same product is currently undergoing Phase III trials for DFU in Europe and is also in Phase II/III studies for venous leg ulcers (VLU) in Germany, where it additionally functions as an anti-infective. Beyond this lead product, CytoTools' development pipeline features Utisept, a urological medical device designed for bladder flushing in urinary tract infections, and Derma MP, another therapy aimed at treating venous leg ulcers in Europe. In earlier stages, CardioClean is a preclinical candidate targeting conditions such as restenosis, diabetes, and carotid stenosis, while Cancer T17-n is an oncology project focused on cancer treatment in Europe. Furthermore, CytoTools has forged a collaboration with Activoris Medizintechnik GmbH to develop an inhalation therapy specifically for viral infections like COVID-19 and influenza. The company is headquartered in Darmstadt, Germany.